Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BONFIRE beta-blocker discontinuation in heart failure with recovered ejection fraction
2023-508798-94-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carvedilol, bisoprolol, metoprolol and nebivolol in heart failure (HF) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite heart failure relapse endpoint. Planned start Feb 2025; status: authorised.
02
Drugs
carvedilolbisoprololmetoprololnebivolol
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2023-508798-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508798-94-00.